159 related articles for article (PubMed ID: 25841471)
1. 5-HT3 receptor antagonists for the treatment of nausea/vomiting.
Smith HS; Cox LR; Smith EJ
Ann Palliat Med; 2012 Jul; 1(2):115-20. PubMed ID: 25841471
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
Haus U; Späth M; Färber L
Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
8. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
Loewen PS; Marra CA; Zed PJ
Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
[TBL] [Abstract][Full Text] [Related]
9. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
11. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
12. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
16. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Burnette PK; Perkins J
Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists.
Tyers MB; Freeman AJ
Oncology; 1992; 49(4):263-8. PubMed ID: 1387926
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action.
Freeman AJ; Cunningham KT; Tyers MB
Anticancer Drugs; 1992 Apr; 3(2):79-85. PubMed ID: 1525396
[TBL] [Abstract][Full Text] [Related]
19. 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
King GL; Rabin BM; Weatherspoon JK
Aviat Space Environ Med; 1999 May; 70(5):485-92. PubMed ID: 10332945
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
